D. Boral Capital upgraded Artelo Biosciences (ARTL) to Buy from Hold with a $20 price target The firm, which has adjusted its model and raised assumptions for the now completed reverse split, continues to view Artelo as an emerging biotechnology company focused on Cachexia and Chemotherapy-induced peripheral neuropathy with the lead program ART27.13, a Phase 2 asset acquired from Astra-Zenca (AZN), the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL: